Xolair Asthma Industry Analysis,Growth and Forecast to 2023

The Report “Xolair (Asthma) – Forecast and Market Analysis to 2023″ is now available at MarketOptimizer.org. Contact sales@marketoptimizer.org with Report name in subject line and your contact details to purchase this report or get your questions answered.

Researcher has released its new PharmaPoint Drug Evaluation report, “Xolair (Asthma) – Forecast and Market Analysis to 2023″. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
Roche/Genentech/Novartis’ Xolair (omalizumab) is currently the only FDA-approved biologic used in the treatment of asthma. This drug is a recombinant humanized mAb that binds and neutralizes IgE with the same high affinity as its cognate receptor, FceRI. The omalizumab-IgE complexes are unable to bind and activate cell membrane-bound receptor, thus preventing the recognition of the allergen by effector cells, including mast cells, eosinophils, and macrophages.

Complete Report is available @ http://www.marketoptimizer.org/xolair-asthma-forecast-and-market-analysis-to-2023.html .

Scope

Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Xolair including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Xolair for the top eight countries from 2013 to 2023.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons To Buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Asthma
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of Xolair performance
Obtain sales forecast for Xolair from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Buy the copy of this Report @ http://www.marketoptimizer.org/contacts/purchase?rname=10537 .

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.1.3 Prognosis

3.1.4 Quality of Life

3.2 Symptoms

4 Disease Management

4.1 Diagnosis and Treatment Overview

4.1.1 Diagnosis

4.1.2 Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs

4.1.3 Clinical Practice

5 Competitive Assessment

5.1 Overview

5.2 Strategic Competitor Assessment

6 Xolair (omalizumab)

6.1 Overview

6.2 Efficacy

Inquiry before buying this Report @ http://www.marketoptimizer.org/contacts/inquire-before-buying?rname=10537 . (Single User License : US$ 3495 And Corporate User License : US$ 10485)

For further information on “Xolair (Asthma) – Forecast and Market Analysis to 2023” report Contact sales@marketoptimizer.org / Call +1 888 391 5441.